Study title: Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of Familial Mediterranean Fever: an analysis of factors affecting outcome. Arthritsis Rheum 1994; 37:1804-1811Livneh A, Zemer D, Langevitz P, Laor A, Sohar E, Pras M. Colchicine treatment of AA amyloidosis of Familial Mediterranean Fever: an analysis of factors affecting outcome. Arthritsis Rheum 1994; 37:1804-1811
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: COLCHICINE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |